Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG009301 in Relapsed or Refractory Haematological Malignancies
NCT07347171Phase 1Recruiting
- Sponsor
- Cullgen Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of CG009301 in hematologic malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (10 arms), sponsored by Cullgen Inc. Primary endpoints: Recommended Dose for Expansion at 8 months, Duration of continuous administration and dosing cycle at 20 months and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
CG009301
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07347171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347171.